123 related articles for article (PubMed ID: 30608147)
21. Novel method for the determination of average molecular weight of natural polymers based on 2D DOSY NMR and chemometrics: Example of heparin.
Monakhova YB; Diehl BWK; Do TX; Schulze M; Witzleben S
J Pharm Biomed Anal; 2018 Feb; 149():128-132. PubMed ID: 29112901
[TBL] [Abstract][Full Text] [Related]
22. Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis.
Dietrich CP; Paiva JF; Castro RA; Chavante SF; Jeske W; Fareed J; Gorin PA; Mendes A; Nader HB
Biochim Biophys Acta; 1999 Aug; 1428(2-3):273-83. PubMed ID: 10434045
[TBL] [Abstract][Full Text] [Related]
23. Reversed-phase ion-pair ultra-high-performance-liquid chromatography-mass spectrometry for fingerprinting low-molecular-weight heparins.
Langeslay DJ; Urso E; Gardini C; Naggi A; Torri G; Larive CK
J Chromatogr A; 2013 May; 1292():201-10. PubMed ID: 23352830
[TBL] [Abstract][Full Text] [Related]
24. The potential for circular dichroism as an additional facile and sensitive method of monitoring low-molecular-weight heparins and heparinoids.
Rudd TR; Skidmore MA; Guimond SE; Holman J; Turnbull JE; Lauder RM; Fernig DG; Yates EA
Thromb Haemost; 2009 Nov; 102(5):874-8. PubMed ID: 19888522
[TBL] [Abstract][Full Text] [Related]
25. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
[TBL] [Abstract][Full Text] [Related]
26. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
27. Novel method for measurement of heparin anticoagulant activity using SPR.
Zhao J; Liu X; Malhotra A; Li Q; Zhang F; Linhardt RJ
Anal Biochem; 2017 Jun; 526():39-42. PubMed ID: 28322799
[TBL] [Abstract][Full Text] [Related]
28. Heparin mapping using heparin lyases and the generation of a novel low molecular weight heparin.
Xiao Z; Tappen BR; Ly M; Zhao W; Canova LP; Guan H; Linhardt RJ
J Med Chem; 2011 Jan; 54(2):603-10. PubMed ID: 21166465
[TBL] [Abstract][Full Text] [Related]
29. Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo.
Poli M; Asperti M; Ruzzenenti P; Mandelli L; Campostrini N; Martini G; Di Somma M; Maccarinelli F; Girelli D; Naggi A; Arosio P
Biochem Pharmacol; 2014 Dec; 92(3):467-75. PubMed ID: 25241290
[TBL] [Abstract][Full Text] [Related]
30. Oligosaccharide mapping of low molecular weight heparins: structure and activity differences.
Linhardt RJ; Loganathan D; al-Hakim A; Wang HM; Walenga JM; Hoppensteadt D; Fareed J
J Med Chem; 1990 Jun; 33(6):1639-45. PubMed ID: 2160537
[TBL] [Abstract][Full Text] [Related]
31. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
Lin P; Sinha U; Betz A
Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
[TBL] [Abstract][Full Text] [Related]
32. Anticoagulant activity of porcine heparin: Structural-property relationship and semi-quantitative estimation by nuclear magnetic resonance (NMR) spectrometry.
Monakhova YB; Fareed J; Yao Y; Diehl BWK
J Pharm Biomed Anal; 2019 Sep; 174():639-643. PubMed ID: 31279893
[TBL] [Abstract][Full Text] [Related]
33. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
[TBL] [Abstract][Full Text] [Related]
34. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent.
Lee Y; Nam JH; Shin HC; Byun Y
Circulation; 2001 Dec; 104(25):3116-20. PubMed ID: 11748110
[TBL] [Abstract][Full Text] [Related]
35. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
36. Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.
Walenga JM; Lyman GH
Crit Rev Oncol Hematol; 2013 Oct; 88(1):1-18. PubMed ID: 23849978
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins.
St Ange K; Onishi A; Fu L; Sun X; Lin L; Mori D; Zhang F; Dordick JS; Fareed J; Hoppensteadt D; Jeske W; Linhardt RJ
Clin Appl Thromb Hemost; 2016 Sep; 22(6):520-7. PubMed ID: 27084870
[TBL] [Abstract][Full Text] [Related]
38. Sequencing the oligosaccharide pool in the low molecular weight heparin dalteparin with offline HPLC and ESI-MS/MS.
Wang Z; Zhang T; Xie S; Liu X; Li H; Linhardt RJ; Chi L
Carbohydr Polym; 2018 Mar; 183():81-90. PubMed ID: 29352895
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive Identification and Quantitation of Basic Building Blocks for Low-Molecular Weight Heparin.
Sun X; Sheng A; Liu X; Shi F; Jin L; Xie S; Zhang F; Linhardt RJ; Chi L
Anal Chem; 2016 Aug; 88(15):7738-44. PubMed ID: 27388010
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of rat smooth muscle cell adhesion and proliferation by non-anticoagulant heparins.
Kazi M; Lundmark K; Religa P; Gouda I; Larm O; Ray A; Swedenborg J; Hedin U
J Cell Physiol; 2002 Dec; 193(3):365-72. PubMed ID: 12384988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
